{"id":"W3132547876","doi":"10.1158/1538-7445.sabcs20-ps12-28","title":"Abstract PS12-28: Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab, and a taxane as first-line therapy for locally advanced/metastatic triple-negative breast cancer (TNBC)","year":2021,"lang":"en","type":"article","venue":"Cancer Research","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada)","funders":"","keywords":"Atezolizumab; Taxane; Medicine; Triple-negative breast cancer; Internal medicine; Oncology; Metastatic breast cancer; Phases of clinical research; Chemotherapy; Population; Breast cancer; Cancer; Response Evaluation Criteria in Solid Tumors; Progression-free survival; Immunotherapy; Pembrolizumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001020159,0.001525436,0.001991314,0.0005156057,0.0004963563,0.0009177642,0.0009615825,0.001046403,0.008357489],"category_scores_gemma":[0.0005539543,0.000673686,0.000868424,0.0005642185,0.0007608077,0.0007137498,0.0004363795,0.003657303,0.002374308],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001022456,"about_ca_system_score_gemma":0.002572019,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001277746,"about_ca_topic_score_gemma":0.003595503,"domain_scores_codex":[0.9996616,0.0001189483,0.0000213661,0.00007642875,0.00004819923,0.00007358447],"domain_scores_gemma":[0.9995833,0.00002872442,0.00006854027,0.00003921224,0.00002327559,0.0002570637],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5932638,0.1205911,0.007304262,0.001569886,0.001463994,0.0005801719,0.0003463628,0.002722923,0.1449283,0.0004273976,0.01239913,0.1144026],"study_design_scores_gemma":[0.488351,0.4850106,0.01193526,0.00004152133,0.0005239553,0.0006390646,0.00006265301,0.0009276181,0.007344,0.0002369349,0.004895353,0.00003201529],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9840703,0.001681225,0.0006736832,0.0005576998,0.000111226,0.005041542,0.003705447,0.0002443861,0.003914475],"genre_scores_gemma":[0.9744301,0.001772181,0.002625371,0.001086937,0.0001727972,0.00545517,0.007388035,0.00008065237,0.006988591],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008357489,"threshold_uncertainty_score":0.02795863,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.159363250679661,"score_gpt":0.5174108302588322,"score_spread":0.3580475795791712,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}